MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
44.63
+3.72
+9.09%
Opening 12:40 08/12 EDT
OPEN
47.01
PREV CLOSE
40.91
HIGH
47.55
LOW
42.43
VOLUME
5.26M
TURNOVER
--
52 WEEK HIGH
49.70
52 WEEK LOW
8.70
MARKET CAP
6.00B
P/E (TTM)
-13.0204
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Eli Lilly & Co (LLY)
TipRanks · 1h ago
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'
Benzinga · 2h ago
Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target
TipRanks · 2h ago
Definium reports strong Phase 3 GAD trial results
TipRanks · 4h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 4h ago
Definium succeeds in late-stage trial for LSD-derived psychiatric therapy
Seeking Alpha · 4h ago
Definium Therapeutics Says Anxiety Treatment Met Primary Endpoint in Late-Stage Trial
Dow Jones · 5h ago
Definium Therapeutics Reports Positive Topline Data From Phase 3 DT120 Study, Stock Up In Pre-Market
NASDAQ · 5h ago
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.